Chronic graft-versus-host disease in the lung
Conditions
Interventions
Pulmonary cGVHD group:None
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) For patients aged 18-50 years who received allogeneic hematopoietic stem cell transplantation and whose pulmonary function tests regularly indicated reduced pulmonary function and excluded infection and other causes, accompanied by or suspected pulmonary diseases (such as bronchiolitis obliterans, diffuse interstitial lung disease, pulmonary fibrosis), lung CT and pulmonary function tests suggested that further pathological evaluation of lung biopsy was needed. Or patients diagnosed with pulmonary cGVHD after allogeneic hematopoietic stem cell transplantation; 2. Voluntarily participate in this study and sign informed consent; 3. Without serious damage of vital organs: (1) creatinine =2g/dl; (3) cardiac ejection index >50%; (4) heme >9g/dL, bilirubin < 2.0mg/dl; 4. Blood routine, liver and kidney function, coagulation routine were normal, and the pre-transfusion examination and hepatitis B screening were all negative. 5. No contraindications to transbronchial cryobiopsy.
Exclusion criteria
Exclusion criteria: 1.Severe complications or high-risk factors: Severe pulmonary insufficiency unable to tolerate biopsy (e.g., arterial oxygen partial pressure 1.5, or platelet count <60×10?/L); recent (e.g., within 4 weeks) severe infection (e.g., pneumonia, sepsis) that has not been controlled. 2.Other pulmonary diseases: Presence of other clear pulmonary etiologies (e.g., tuberculosis, fungal infection, malignancy) that are not clearly associated with pulmonary cGVHD. 3.Poor general condition: ECOG score =3 or estimated survival <3 months; severe cardiopulmonary impairment (e.g., NYHA cardiac function class III or IV). 4.Contraindications to anesthesia or biopsy: Known contraindications to anesthesia or biopsy (e.g., history of anesthesia allergy, unmanageable airway issues), inability to fully understand or consent to study-related procedures and risks. 5.Clinical symptoms of cerebral dysfunction or severe mental illness that prevent understanding or adherence to the study protocol. 6.Patients with severe acute allergic reactions. 7.Other reasons deemed unsuitable for clinical trial participation by the study investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cell-Cell Interaction Analysis Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Shannon index;Spatial Interaction Score; | — |
Countries
China
Contacts
Public ContactZhang xi
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed